Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): More or all solvent used
There is more diluent in the diluent vial than is needed to complete the reconstitution. If more diluent is added than directed in the instructions for use, the final dose will be less than 150 mg/ml. This can lead to an incorrect dose being administered.
Lilly cannot provide guidance to use the product in a way that is not specified in the label.1
Solvent Volume for Reconstitution
Table 1 provides the amount of solvent required to reconstitute olanzapine pamoate powder for prolonged release suspension for injection.2
Table 1. Determine the amount of solvent required to reconstitute olanzapine pamoate powder for prolonged release suspension for injection.2
|
ZypAdhera vial strength (mg) |
Volume of solvent to add (ml) |
|
210 |
1.3 |
|
300 |
1.8 |
|
405 |
2.3 |
It is important to note that there is more solvent in the vial than is needed to reconstitute.
Each vial of solvent across all strengths contains 3 ml of solvent.2
After reconstitution as directed in the label, each ml of suspension contains 150 mg olanzapine.2
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.
Date of Last Review: February 13, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays